Q-omics provides the consensus-scored RPS6P12 profile across patient tissues and cancer cell-line models. RPS6P12 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS6P12 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RPS6P12 RNA expression shows 6,866 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where RPS6P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P12 survival associations across molecular data types. RPS6P12 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P12 RNA expression–survival associations across cancer types. High RPS6P12 expression shows unfavorable associations in KIRC, SKCM, KICH, CHOL and THCA, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS6P12 RNA expression.
This table summarizes RPS6P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P12 shows higher tumor expression in HNSC, BLCA, UCEC, LUAD, STAD and LUSC. The HNSC box plot shows higher RPS6P12 RNA expression in tumor versus normal tissue (log2 FC = +0.342, t-test p < 0.001).
This table shows molecular features associated with RPS6P12 in patient tissues and cancer cell lines. In patient samples, RPS6P12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
